<DOC>
	<DOCNO>NCT01597245</DOCNO>
	<brief_summary>This study ass safety efficacy ixekizumab ( LY2439821 ) compare etanercept placebo participant moderate severe chronic plaque psoriasis .</brief_summary>
	<brief_title>A Phase 3 Study Participants With Moderate Severe Psoriasis ( UNCOVER-2 )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Present chronic plaque psoriasis base confirm diagnosis chronic plaque psoriasis least 6 month prior first dose study drug At least 10 % Body Surface Area ( BSA ) psoriasis screen first dose study drug Static Physician Global Assessment ( sPGA ) score least 3 Psoriasis Area Severity Index ( PASI ) score least 12 screen first dose study drug Candidate phototherapy and/or systemic therapy Men must agree use reliable method birth control remain abstinent study Women must agree use reliable birth control remain abstinent study least 12 week stop treatment Pustular , erythrodermic , and/or guttate form psoriasis History druginduced psoriasis Prior use etanercept Clinically significant flare psoriasis 12 week prior randomization Concurrent recent use biologic agent Received nonbiologic systemic psoriasis therapy phototherapy ( include psoralens ultraviolet A [ PUVA ] , ultraviolet B [ UVB ] ) within previous 4 week ; topical psoriasis treatment within previous 2 week prior randomization Can avoid excessive sun exposure use tan booth least 4 week prior randomization study Have participate study interleukin 17 ( IL17 ) antagonist , include ixekizumab Serious disorder illness plaque psoriasis Serious infection within last 3 month Breastfeeding nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>